Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Riboflavin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.71 |
| ▸ | NR3C1 known ✓ | P04150 | 1/20 | 0.71 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.71 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.71 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.71 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.71 |
| ▸ | AGTR1 known ✓ | P30556 | 1/20 | 0.71 |
| ▸ | NTRK1 known ✓ | P04629 | 1/20 | 0.43 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 7/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.96 |
| ▸ | USP2 | O75604 | 4/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.96 |
| ▸ | HAT1 | O14929 | 4/20 | 0.96 |
| ▸ | RBBP7 | Q16576 | 4/20 | 0.96 |
| ▸ | HTT | P42858 | 4/20 | 0.96 |
| ▸ | RECQL | P46063 | 3/20 | 0.96 |
| ▸ | CASP7 | P55210 | 3/20 | 0.96 |
| ▸ | MAPT | P10636 | 3/20 | 0.96 |
| ▸ | CASP1 | P29466 | 2/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Riboflavin SCHEMBL1064647 | 1.00 | MEN1 (0.96) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL4380877 | 0.99 | MEN1 (0.98) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL5084898 | 0.99 | MEN1 (0.98) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL1983532 | 0.99 | MEN1 (0.98) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL5084919 | 0.99 | MEN1 (0.98) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL15513459 | 0.98 | MEN1 (0.96) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL6364649 | 0.98 | MEN1 (0.96) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL28003822 | 0.98 | MEN1 (0.96) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL7707 | 0.98 | MEN1 (1.00) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL12979917 | 0.98 | MEN1 (1.00) | MEN1KMT2AUSP2KDM4EHAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024090652-A1 | WATER-SOLUBLE MILK THISTLE AND METHOD FOR PREPARING SAME | 주식회사 보고신약 | 2024-05-02 | — | — | WO | disclosed |
| WO-2023191515-A1 | COMPOSITION FOR PREVENTING HAIR LOSS OR PROMOTING HAIR GROWTH COMPRISING INDIRUBIN DERIVATIVE AND METABOLIC ACTIVATOR | 연세대학교 산학협력단 | 2023-10-05 | — | — | WO | disclosed |
| US-11773081-B2 | Pharmaceutical composition for preventing or treating wound, comprising indirubin derivative as active ingredient | CK REGEON INC. (KR) | 2023-10-03 | — | — | US | disclosed |
| US-20230257434-A1 | CELL-DERIVED VESICLES COMPRISING TARGET PROTEIN AND METHOD FOR PRODUCING SAME | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2023-08-17 | — | — | US | disclosed |
| WO-2023106777-A1 | VITAL MELON (KCTC14699BP) AND ANTI-OBESITY COMPOSITION COMPRISING EXTRACT THEREOF | 광동제약 주식회사 | 2023-06-15 | — | — | WO | disclosed |
| EP-3662891-B1 | COMPOSITION FOR PREVENTING HAIR LOSS OR PROMOTING HAIR GROWTH | CK REGEON INC (KR) | 2023-06-07 | — | — | EP | disclosed |
| CN-111093620-B | Composition for preventing hair loss or promoting hair growth | CK雷容股份有限公司 | 2023-05-05 | — | — | CN | disclosed |
| US-20230105449-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING WOUND, COMPRISING INDIRUBIN DERIVATIVE AS ACTIVE INGREDIENT | CK BIOTECH (KR) | 2023-04-06 | — | — | US | disclosed |
| EP-4026550-A1 | COMPOSITION FOR PREVENTING OR TREATING SALIVARY GLAND DISESAES USING CELL-DERIVED VESICLE | MDimune Inc. (KR) | 2022-07-13 | — | — | EP | disclosed |
| CN-114599380-A | Composition for preventing or treating salivary gland diseases using cell-derived vesicle | 美德邈医药公司 | 2022-06-07 | — | — | CN | disclosed |
| WO-2005120534-A1 | PONCIRUS TRIFOLIATA EXTRACT FOR PREVENTING AND TREATING ISCHEMIC HEART DISEASES AND PHAR¬ MACEUTICAL COMPOSITION AND HEALTH FOOD CONTAINING THE SAME | PURIMED CO., LTD. (KR) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005120533-A1 | POLYGALA TENUIFOLIA EXTRACT FOR PREVENTING AND TREATING ISCHEMIC HEART DISEASE AND PHAR¬ MACEUTICAL COMPOSITION AND HEALTH FOOD CONTAINING THE SAME | PURIMED CO., LTD. (KR) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005120532-A1 | NELUMBINIS SEMEN EXTRACT FOR PREVENTING AND TREATING ISCHEMIC HEART DISEASE AND PHARMACEUTICAL COMPOSITION AND HEALTH FOOD CONTAINING THE SAME | PURIMED CO., LTD. (KR) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005112912-A1 | IMMUNOMODUATING AGENT, ANTI-CANCER AGENT AND HEALTH FOOD CONTAINING MONOACETYLDIACYLGLYCEROL DERIVATIVES | KIM SANG-HEE (KR) | 2005-12-01 | — | — | WO | disclosed |
| WO-2005074963-A1 | COMPOSITION FOR PREVENTION AND TREATMENT OF DIABETIC COMPLICATION | KOREA INSTITUTE OF ORIENTAL MEDICINE (KR) | 2005-08-18 | — | — | WO | disclosed |
| WO-2005067404-A2 | HEALTH FOOD CONTAINING DISTILLED PINE-NEEDLE EXTRACT | BAE GWANG SEOK (KR) | 2005-07-28 | — | — | WO | disclosed |
| WO-2005063232-A1 | OBESITY AND METABOLIC SYNDROME TREATMENT WITH TANSHINONE DERIVATIVES WHICH INCREASE METABOLIC ACTIVITY | MD BIOALPHA CO., LTD. (KR) | 2005-07-14 | — | — | WO | disclosed |
| WO-2005025588-A1 | EXTRACT OF OGALPI, ERECTILE DYSFUNCTION FANNING HEALTHY FOOD AND ERECTILE DYSFUNCTION TREATING AGENT CONTAINING THE SAME | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2005-03-24 | — | — | WO | disclosed |
| WO-2005021021-A1 | EXTRACT OF NELUMBINIS SEMEN FOR THE TREATMENT OF DEPRESSION | PURIMED CO., LTD. (KR) | 2005-03-10 | — | — | WO | disclosed |
| WO-2003092710-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN EXTRACT OF PELVETIA SILIQUOSA FOR THE PREVENTION OR THE TREATMENT OF LIVER DISEASE, DIABETES AND DIABETIC COMPLICATIONS | SHIN KUK HYUN (KR) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773081-B2 | Pharmaceutical composition for preventing or treating wound, comprising indirubin derivative as active ingredient | HES1, SHMT1, KDM5C | ESR1 3363/4885NR3C1 3686/4885ADRB2 4498/4885 |
| US-20230105449-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING WOUND, COMPRISING INDIRUBIN DERIVATIVE AS ACTIVE INGREDIENT | HES1, SHMT1, KDM5C | ESR1 3363/4885NR3C1 3686/4885ADRB2 4498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.